investment

Google Stock Remains A Mutual Fund Darling — And Near A Buy Zone

KIMBERLEY KOENIG

2 min read

0 likes

⚡ Quantum Brief

Alphabet’s parent company stock is nearing a buy zone after forming a flat base, signaling potential upward momentum in February 2026. Institutional investors continue to favor the tech giant. The stock was highlighted alongside three others—Coterra Energy, Vistance Networks, and an unnamed fourth—on a screen tracking mutual fund purchases. Big-money backing often drives share price growth. The "Magnificent Seven" tech firms, including Alphabet, are aggressively investing in AI infrastructure, prioritizing scale and compute over traditional margin-focused earnings strategies. China’s biotech sector is rapidly evolving from generic drug production to innovation, though this was noted as a secondary market trend unrelated to Alphabet’s stock performance. Investor’s Business Daily emphasized that historical performance doesn’t guarantee future results, cautioning readers about market volatility and the speculative nature of stock recommendations.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

BREAKING: Stocks Mixed As Datadog, Marriott Rally Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience.Google stock parent Alphabet (GOOGL) is joined by three other names appearing the IBD Screen Of The Day list. Institutional backing is a key component in stock performance, as large purchases by big money managers can help lift share price.

The Stocks That Funds Are Buying screen also found three other names worth highlighting: Coterra Energy (CTRA), Vistance Networks (VISN)…(gguy - stock.adobe.com) 5:46 AM ET The Mag 7 are spending heavily on AI infrastructure, shifting the focus of earnings from margins to scale, compute and... 5:46 AM ET The Mag 7 are spending heavily on AI infrastructure, shifting... Long known for generic drugs and fast-follower copycats, China is quickly emerging as a biotech trailblazer. (© Chris Gash)Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!Get market updates, educational videos, webinars, and stock analysis.Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.©2026 Investor’s Business Daily, LLC.

Read Original

Source Information

Source: Investor's Business Daily

Website: https://www.investors.com/feed/

Discussion

0 professional contributions

Be the first to add a constructive contribution.